Prevalence of Potential Schistosome Hybrids and Their Invasive Capacity Under Praziquantel Pressure in Northern Senegal
试验速览
- 阶段
- 不适用
- 入组人数
- 250
- 试验地点
- 1
- 主要终点
- Change from baseline in prevalence and intensity of schistosome infection
研究概览
简要总结
The overall objective of this project is to examine and quantify the potential existence and impact on Praziquantel (PZQ) efficacy, of naturally occurring S. haematobium and S. bovis hybrid populations in northern Senegal. Schistosome hybrids may present vigor compared to their pure parental forms and hence, may be less sensitive to PZQ. We hypothesise that PZQ repeated treatment selects the hybrid schistosome populations.
详细描述
Human schistosomiasis is a Neglected Tropical Disease caused by schistosome helminth worms with impressive epidemiological statistics associated: 800 million people at risk in 78 countries, > 230 million infected and > 200 000 deaths each year. The disease is highly endemic in sub-Saharan Africa where it persists despite mass drug administration with Praziquantel (PZQ). Some schistosomes are specific to humans and induce two main disease forms (either mesenteric or uro-genital) while others are associated with wild animals. However, hybridization can occur between different schistosome species. In northern Senegal, hybridization between schistosome species specific to humans and animals is now known to be frequent with the potential risk of zoonotic transmission.
This study will propose an integrative approach by conducting parasitological and molecular analysis including, schistosome miracidia genotyping to show if PZQ repeated treatment affects the genomic composition (Frequencies of alleles) of hybrid populations.
The objectives are:
- Determine the current prevalence of potential hybrid schistosome populations in their natural setting in Senegal
- Determine the sensitivity of hybrid schistosomes to praziquantel treatment in field populations
- Determine the molecular basis (at the genome level) of such phenotypic changes).
The study is a longitudinal observation of a cohort of school children after repeated Praziquantel (40 mg/kg) treatment, a drug commonly used through Mass Drug Administration (MDA) to treat schistosomiasis.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 5 Years 至 10 Years(Child)
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Children between the initiation courses (CI) and elementary course second year (CE2)
- •Absence of declared chronic pathologies that could impact the follow-up
- •Be positive for S. haematobium infection during the selection period (excreting eggs)
- •Residing in the study area during the 3 years of the follow-up
排除标准
- •Absence of written informed consent or expressed refusal from the child
- •Enrolled in another on going study, which implicates the administration of PZQ or tests another product.
结局指标
主要结局
Change from baseline in prevalence and intensity of schistosome infection
时间窗: December 31. 2020
Determine at the 1 month post treatment the cure rate (CR) of the treatments and Egg Reduction Rates (ERR).
次要结局
- Hybrids tolerance to praziquantel(December 31, 2021)
